Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Statins and nonalcoholic fatty liver disease in the era of precision medicine: More friends than foes
Fabio Nascimbeni, Elisa Pellegrini, Simonetta Lugari, et al.
Atherosclerosis (2019) Vol. 284, pp. 66-74
Closed Access | Times Cited: 74

Showing 1-25 of 74 citing articles:

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review
Wah‐Kheong Chan, Kee Huat Chuah, Ruveena Bhavani Rajaram, et al.
Journal of Obesity & Metabolic Syndrome (2023) Vol. 32, Iss. 3, pp. 197-213
Open Access | Times Cited: 265
Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management
Thomas Marjot, Ahmad Moolla, Jeremy Cobbold, et al.
Endocrine Reviews (2019) Vol. 41, Iss. 1, pp. 66-117
Open Access | Times Cited: 192
Hepatic cholesterol transport and its role in non-alcoholic fatty liver disease and atherosclerosis
Heng Li, Xiao-Hua Yu, Xiang Ou, et al.
Progress in Lipid Research (2021) Vol. 83, pp. 101109-101109
Closed Access | Times Cited: 150
Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies
Mohammad Habibullah, Khaleed Jemmieh, Amr Ouda, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 30
Inadequate Physical Activity and Sedentary Behavior Are Independent Predictors of Nonalcoholic Fatty Liver Disease
Donghee Kim, Luis Miguel Vazquez‐Montesino, Andrew A. Li, et al.
Hepatology (2020) Vol. 72, Iss. 5, pp. 1556-1568
Closed Access | Times Cited: 121
Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease
Juan Pablo Arab, Melisa Dirchwolf, Mário Reis Álvares‐da‐Silva, et al.
Annals of Hepatology (2020) Vol. 19, Iss. 6, pp. 674-690
Open Access | Times Cited: 109
Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
Golnaz Ranjbar, Dimitri P. Mikhailidis, Amirhossein Sahebkar
Metabolism (2019) Vol. 101, pp. 154001-154001
Closed Access | Times Cited: 94
Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes
Stefano Ciardullo, Gianluca Perseghin
Metabolism (2021) Vol. 121, pp. 154752-154752
Closed Access | Times Cited: 81
Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management
Amedeo Lonardo, Juan Pablo Arab, Marco Arrese
Advances in Therapy (2021) Vol. 38, Iss. 5, pp. 2130-2158
Open Access | Times Cited: 67
Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease
Anna Martin, Sonja Lang, Tobias Goeser, et al.
Current Atherosclerosis Reports (2022) Vol. 24, Iss. 7, pp. 533-546
Open Access | Times Cited: 49
Ferroptosis, a new pathogenetic mechanism in cardiometabolic diseases and cancer: Is there a role for statin therapy?
Amirhossein Sahebkar, Zahra Foroutan, Niki Katsiki, et al.
Metabolism (2023) Vol. 146, pp. 155659-155659
Closed Access | Times Cited: 32
Metabolic dysfunction-associated steatotic liver disease and extrahepatic gastrointestinal cancers
Alessandro Mantovani, Amedeo Lonardo, Norbert Stefan, et al.
Metabolism (2024) Vol. 160, pp. 156014-156014
Closed Access | Times Cited: 11
Hepatic‐Accumulated Obeticholic Acid and Atorvastatin Self‐Assembled Nanocrystals Potentiate Ameliorative Effects in Treatment of Metabolic‐Associated Fatty Liver Disease
Huanfen Lu, Zhenglan Ban, Kai Xiao, et al.
Advanced Science (2024) Vol. 11, Iss. 10
Open Access | Times Cited: 10
Association of NAFLD/NASH, and MAFLD/MASLD with chronic kidney disease: an updated narrative review
Amedeo Lonardo
Metabolism and Target Organ Damage (2024) Vol. 4, Iss. 2
Open Access | Times Cited: 9
Executive summary of the Hellenic Atherosclerosis Society guidelines for the diagnosis and treatment of dyslipidemias - 2023
Niki Katsiki, Theodosios D. Filippatos, Charalambos Vlachopoulos, et al.
Atherosclerosis Plus (2024) Vol. 55, pp. 74-92
Open Access | Times Cited: 8
A mutation in LXRα uncovers a role for cholesterol sensing in limiting metabolic dysfunction-associated steatohepatitis
Alexis T. Clark, Lillian Russo-Savage, Luke A. Ashton, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis
Maryam Mahjoubin‐Tehran, Antonio De Vincentis, Dimitri P. Mikhailidis, et al.
Molecular Metabolism (2020) Vol. 50, pp. 101049-101049
Open Access | Times Cited: 59
Statins’ efficacy in non-alcoholic fatty liver disease: A systematic review and meta-analysis
Chrysoula Boutari, Panagiotis D. Pappas, Dimitrios A. Anastasilakis, et al.
Clinical Nutrition (2022) Vol. 41, Iss. 10, pp. 2195-2206
Closed Access | Times Cited: 30
3D multi-cell-type liver organoids: A new model of non-alcoholic fatty liver disease for drug safety assessments
Julie Bronsard, Camille C. Savary, Julie Massart, et al.
Toxicology in Vitro (2023) Vol. 94, pp. 105728-105728
Open Access | Times Cited: 19
Statin can reduce the risk of hepatocellular carcinoma among patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis
Jie Zhang, Shifeng Fu, Deliang Liu, et al.
European Journal of Gastroenterology & Hepatology (2023) Vol. 35, Iss. 4, pp. 353-358
Closed Access | Times Cited: 18
Adipocentric origin of the common cardiometabolic complications of obesity in the young up to the very old: pathophysiology and new therapeutic opportunities
Riccardo Sarzani, Matteo Landolfo, Chiara Di Pentima, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 6
Statins on nonalcoholic fatty liver disease: A systematic review and meta-analysis of 14 RCTs
Haiyan Zhou, Maeda Toshiyoshi, Wenli Zhao, et al.
Medicine (2023) Vol. 102, Iss. 26, pp. e33981-e33981
Open Access | Times Cited: 15
Effect of statin use on liver enzymes and lipid profile in patients with Non-Alcoholic Fatty Liver Disease (NAFLD)
Anh Ho, Takako Kiener, Quynh‐Nhu Nguyen, et al.
Journal of clinical lipidology (2024) Vol. 18, Iss. 4, pp. e501-e508
Open Access | Times Cited: 5
Gallic Acid Can Promote Low-Density Lipoprotein Uptake in HepG2 Cells via Increasing Low-Density Lipoprotein Receptor Accumulation
Dongying Zhang, Qixing Zhou, Xiangxuan Yang, et al.
Molecules (2024) Vol. 29, Iss. 9, pp. 1999-1999
Open Access | Times Cited: 5
Liver X receptors and liver physiology
Lillian Russo-Savage, Ira G. Schulman
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2021) Vol. 1867, Iss. 6, pp. 166121-166121
Open Access | Times Cited: 32
Page 1 - Next Page

Scroll to top